Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Climb Bio, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 68 | 2 | 65 | −1 |
| Shares | 44.6M | 49.5K | 31.2M | −13.4M (−30.0%) |
| Value | $89.7M | $99.6K | $157.4M | +$67.8M (+75.7%) |
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Climb Bio, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| MPM Oncology Impact Management LP | 2,671,480 | $10.7M | 1.22% |
| Great Point Partners LLC | 979,534 | $3.92M | 1.27% |
| Point72 Asset Management, L.P. | 716,680 | $2.87M | 0.00% |
| Driehaus Capital Management LLC | 600,946 | $2.40M | 0.02% |
| Kotler Kevin | 400,000 | $1.60M | 1.18% |
| Citadel Advisors LLC | 239,043 | $956.2K | 0.00% |
| 683 Capital Management, LLC | 201,652 | $806.6K | 0.07% |
| Ameriprise Financial Inc | 139,529 | $558.1K | 0.00% |
| Botty Investors LLC | 121,400 | $485.6K | 0.12% |
| Squadron Capital Management LLC | 100,000 | $400.0K | 0.18% |
| Omers Administration Corp | 85,466 | $341.9K | 0.00% |
| Seven Fleet Capital Management LP | 76,400 | $305.6K | 0.21% |
| Hudson Bay Capital Management LP | 48,736 | $194.9K | 0.00% |
| Balyasny Asset Management LLC | 14,236 | $56.9K | 0.00% |
| Blair William & Co | 11,000 | $44.0K | 0.00% |
| Virtu Financial LLC | 10,655 | $43.0K | 0.00% |
| Scientech Research LLC | 10,428 | $41.7K | 0.03% |
Sold out (18)
Institutions that held Climb Bio, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Tang Capital Management LLC | 1,000,000 | $2.01M |
| Cantor Fitzgerald, L. P. | 547,173 | $1.10M |
| Deep Track Capital, LP | 509,789 | $1.02M |
| Alyeska Investment Group, L.P. | 485,364 | $975.6K |
| Shay Capital LLC | 150,000 | $301.5K |
| Diadema Partners LP | 136,488 | $274.3K |
| Bluefin Capital Management, LLC | 59,985 | $120.6K |
| Susquehanna Portfolio Strategies, LLC | 18,272 | $36.7K |
| Squarepoint Ops LLC | 17,699 | $35.6K |
| Walleye Capital LLC | 15,000 | $30.1K |
| China Universal Asset Management Co., Ltd. | 11,878 | $23.9K |
| Federated Hermes, Inc. | 4,420 | $8.88K |
| Mirae Asset Global Investments Co., Ltd. | 2,620 | $5.27K |
| GF Fund Management Co. Ltd. | 1,458 | $2.93K |
| EverSource Wealth Advisors, LLC | 224 | $450 |
| SRS Capital Advisors, Inc. | 53 | $106 |
| Advisory Services Network, LLC | 32 | $64 |
| SBI Securities Co., Ltd. | 13 | $26 |
Not filed for Q4 2025 yet (2)
Institutions that held Climb Bio, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Cubist Systematic Strategies, LLC | 38,591 | $77.6K |
| Point72 Asia (Singapore) Pte. Ltd. | 10,952 | $22.0K |